TIL: Instil Bio, Inc. Stock

by  •  • Comments Off on TIL: Instil Bio, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 125.23
Enterprise Value ($M) 200.74
Book Value ($M) 176.33
Book Value / Share 27.02
Price / Book 0.71
NCAV ($M) 36.34
NCAV / Share 5.57
Price / NCAV 3.45

Profitability (mra)
Return on Invested Capital (ROIC) -0.28
Return on Assets (ROA) -0.23
Return on Equity (ROE) -0.33

Liquidity (mrq)
Quick Ratio 12.90
Current Ratio 12.90

Balance Sheet (mrq) ($M)
Current Assets 132.57
Assets 272.56
Liabilities 96.23
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -56.05
Net Income -74.14

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-13 13G/A BML Investment Partners, L.P. 6.70 27.10
11-14 13G/A Vivo Capital IX, LLC 9.00 -95.31
11-14 13G/A Venrock Healthcare Capital Partners II, L.P. 0.50 -99.52
10-25 13G/A Boxer Capital Management, LLC 5.50
10-22 13D/A Curative Ventures V LLC 36.80 -94.10
09-27 13G Boxer Capital, LLC 5.50
09-27 13G Perceptive Advisors Llc 5.30

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-04 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTI
2024-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-03-21 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-03-07 22,003 73,158 30.08
2025-03-06 11,641 54,075 21.53
2025-03-05 10,807 46,133 23.43
2025-03-04 34,589 154,489 22.39

(click for more detail)

Similar Companies
TGTX – TG Therapeutics, Inc. THAR – Tharimmune, Inc.
THTX – Theratechnologies Inc. TLSA – Tiziana Life Sciences Ltd
TNFA – TNF Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io